Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib and Oral Contraceptive PK Interaction
NCT02705963Phase 1Completed
- Sponsor
- Novartis
- Start
- Oct 2016
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of trametinib in solid tumor, sponsored by Novartis. Primary endpoints: Area under the concentration-time curve over the dosing interval for Norethindrone and Ethinyl Estradiol at Day 22, Area under the concentration-time curve from time zero to the last measurable concentration for Norethindrone and Ethinyl Estradiol at Day 22 and 2 more. Started Oct 2016; status: completed.
02
Drugs
trametinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02705963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02705963.